Lower Tamiflu sales hit Chugai but oncology strong
This article was originally published in Scrip
Executive Summary
A sharp drop in sales of flu drug Tamiflu (oseltamivir) dragged down revenues and profits at Roche's Japanese subsidiary Chugai in calendar 2010, although there was again strong underlying growth in the oncology sector.